(HM)-SCREEN-Japan 01 Program Bringing Precision Medicine Research to AML Patients in Japan

Iqra Farooq with AML Global Portal writes the prognosis of younger patients with acute myeloid leukemia (AML) has improved with the development of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and advanced supportive care. But, in most elderly patients with AML, the poor outcomes remain the norm.  Consequently, Japanese researchers are assessing less toxic targeted agents that can be employed alone or in combination with other treatments as needed.

The (HM)-SCREEN-Japan 01 program seeks to establish precision medicine and novel molecular target therapies in Japanese patients with AML. TrialSite News summarizes segments of this article.  Select the link below for a comprehensive read at the source.

The Program

Hematologic malignancies (HM)-SCREEN-Japan is a genetic sequencing project conducted by Japan’s National Cancer Center Hospital. It has been set up to develop effective drugs against AML, as well as to assist with the rapid introduction of new diagnostic techniques.

(FoundationOne®Heme, F1H), a comprehensive genome profiling assay, was evaluated as part of the program.  The assay offers a comprehensive genetic profile that applies NGS to identify somatic genomic alterations. An inclusion criteria for new patients includes a histologically confirmed newly diagnosed AML; elderly and not fit for standard treatment moreover the specimens must be fit for genetic analysis.

The primary focus targets the estimation of frequency of each leukemia gene alteration while the secondary focus centers on the evaluation of association between each leukemia genome mutation and clinicopathological characteristics or prognosis.


After a review of AML genetic mutation studies it is concluded that the data could help shape prognosis through better testing of targeted treatment options for elderly AML patients. The sponsors of the  HM-SCREEN-Japan program seeks to identify and treat targetable mutations in elderly Japanese patients battling AML. It is clear, however, that more large scale studies in biologically homogenous populations will be needed to achieve these objectives.

Lead Research/Investigators

Kenichi Miyamoto, Department of Hematology, National Cancer Centre Hospital, Japan

Yosuke Minami, Department of Hematology, National Cancer Centre Hospital, Japan